Skip to main content

Table 4 Correlations between surrogate endpoints and OS

From: Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation

Surrogate endpoint RCTs before 2012
(1974–2012)
RCTs after 2012
(2013–2017)
Total RCTs
R2 (95% CI) R2 (95% CI) R2 (95% CI)
PFS 0.459 (0.216–0.774) 0.586 (0.319–0.852) 0.557 (0.326–0.788)
3-month PFS 0.103 (0.0–0.332) 0.255 (0.0–0.572) 0.200 (0.0–0.453)
6-month PFS 0.344 (0.037–0.651) 0.386 (0.064–0.708) 0.073 (0.0–0.250)
RR 0.357 (0.064–0.650) 0.228 (0.0–0.539) 0.278 (0.020–0.536)
  1. Abbreviations: CI, confidence interval; HR, hazard ratio; OR, odds ratio; OS, overall survival; PFS, progression-free survival; RCT, randomized controlled trial; RR, response rate